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Abstract
A functional B-cell receptor (BCR) is critical for survival of normal B-cells, but whether it plays a comparable role in B-cell
malignancy is as yet not fully delineated. Typical Hairy Cell Leukemia (HCL) is a rare B-cell tumor, and unique in expressing
multiple surface immunoglobulin (sIg) isotypes on individual tumor cells (mult-HCL), to raise questions as to their functional
relevance. Typical mult-HCL also displays a mutated BRAF V(600)E lesion. Since wild type BRAF is a primary conduit for
transducing normal BCR signals, as revealed by deletion modelling studies, it is as yet not apparent if mutated BRAF alters
BCR signal transduction in mult-HCL. To address these questions, we examined BCR signalling in mult-HCL cases uniformly
displaying mutated BRAF and IGHV genes. Two apparent functional sets were delineated by IgD co-expression. In sIgD+ve
mult-HCL, IgD mediated persistent Ca2+ flux, also evident via .1 sIgH isotype, linked to increased ERK activation and BCR
endocytosis. In sIgD2ve mult-HCL however, BCR-mediated signals and downstream effects were restricted to a single sIgH
isotype, with sIgM notably dysfunctional and remaining immobilised on the cell surface. These observations reveal
discordance between expression and function of individual isotypes in mult-HCL. In dual sIgL expressing cases, only a single
sIgL was fully functional. We examined effects of anti-BCR stimuli on mult-HCL survival ex-vivo. Significantly, all functional
non-IgD isotypes increased ERK1/2 phosphorylation but triggered apoptosis of tumor cells, in both subsets. IgD stimuli, in
marked contrast retained tumor viability. Despite mutant BRAF, BCR signals augment ERK1/2 phosphorylation, but isotype
dictates functional downstream outcomes. In mult-HCL, sIgD retains a potential to transduce BCR signals for tumor survival
in-vivo. The BCR in mult-HCL emerges as subject to complex regulation, with apparent conflicting signalling by individual
isotypes when co-expressed with sIgD. This suggests the possibility that mutant BRAF by-passes BCR constraints in mult-
HCL.
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Introduction
Hairy cell leukaemia (HCL) is a rare B cell leukaemia with
characteristic hair-like cytoplasmic projections on tumor cells,
displaying distinctive activation markers FMC7, CD103, CD25
and CD11c [1]. A striking feature is the expression of multiple
variant surface immunoglobulin (sIg) isotypes on individual tumor
cells, in the major subset of disease (mult-HCL) [1].
Seminal studies have established that a functional BCR is
essential for survival of normal B-cells, enabling response to
cognate antigen or tonic, antigen-independent stimuli [2]. The
BCR is a functional complex of sIg flanked by an Iga/Igb
heterodimer with immunoreceptor tyrosine-based activation mo-
tifs (ITAMs) in cytoplasmic tails [3]. Cross-linking of BCR by
antigen triggers phosphorylation of ITAMs by upstream phos-
photyrosine kinases (PTKs) as constituents of the early signalo-
some. Mammalian wild type BRAF plays an essential role in BCR
function, belonging to the RAF family of three cytosolic kinases (A-
RAF, B-RAF, C-RAF) that function in the RAS-RAF-MEK-ERK
signal transduction, or mitogen-activated protein kinase (MAPK)
pathway, a central conduit for survival and proliferation [4]. RAS
GTPase proteins activate RAF kinases via dimerization, and the
RAF kinases have a restricted substrate specificity to phosphor-
ylate MEK1 and MEK 2 (MEK: MAP/ERK kinase). In turn, the
MEK1/2 dual-specificity protein kinases mediate phosphorylation
of tyrosine and threonine in ERK1 and ERK2, their only known
physiological substrates to date. ERK1/2 on the other hand, have
.175 known cytoplasmic and nuclear (including c-Fos, Elk1, Ets1,
SP-1) downstream substrates as targets, to signal via diverse
pathways to reflect initial stimuli (Review, [4]). Importantly, use of
inducible deletion models have shown that wild type BRAF is the
critical kinase that transduces BCR signals to activate ERK1/2
using the chicken DT40 B-cell line [5]. Birds encode B-RAF and
C-RAF (Raf-1) orthologues but lack a A-RAF equivalent, and in
these studies B-raf was identified as the dominant kinase that
mediates BCR signals for ERK1/2 activation in B-cells, with an
accessory role for Raf-1 [5].
The response of normal B-cells to antigen is stage and context
dependent [3,6–9]. Naive B-cells stimulated by antigen undergo
apoptosis unless rescued by co-stimulatory signals [7–9]. In
response to T-cell independent antigens, such as bacterial
polysaccharides, specific splenic B-cell subsets are recruited at
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extrafollicular sites to differentiate locally [6,10]. In response to T-
cell dependent antigens, follicular B-cells are recruited to the
germinal center (GC) reaction in secondary lymphoid follicles, to
initiate somatic hypermutation (SHM) of Ig variable (IGV) region
genes [11]. Deletional isotype class switch recombination (CSR)
can follow, to in general yield B-cells expressing a single isotype
switched IgH. Both SHM and CSR depend on the enzyme
activation induced cytidine deaminase (AID) [12]. Cessation of
GC events generates durable IgM+ or isotype class switched
memory B-cells that have improved affinity for antigen [11], and
generally express CD27 [13].
Whether the BCR plays a comparable role in sustaining survival
in malignant B-cells is less well characterized and remains a central
question in understanding origins and progression of mature B-cell
neoplasms. A role for antigen recognition by the BCR in selection
of the tumor clone or driving persistence via the BCR has been
investigated in diverse B-cell tumors: it is clear that signalling via
the BCR is implicated, as recent data from genome sequencing
highlights abnormalities in key downstream pathways such as
CARD11 in DLBCL, and constitutive activation of the PI3K
pathway in lymphoma, or that the BCR itself is selectively
modified to promote tumor: niche interactions, as in follicular
lymphoma to potentially bypass a requirement for antigen
(Review, [14]).
In mult-HCL, the functional role of BCR in primary tumor cells
has not been examined to date. Most mult-HCL tumors exhibit
SHM with a low level of on-going mutations and AID expressed,
implicating initial contact with antigen via the BCR [1,15,16]. The
pathway(s) that progress transformation however are as yet not
fully mapped. Interestingly, whole exome sequencing in typical
HCL identified mutant BRAF V(600)E as almost universal in this
tumor type [17]. There are also cases that lack this mutation,
frequently expressing IGHV4-34 genes, in which pathogenesis may
differ [18]. Consistent with mutant BRAF V(600)E, ERK1/2 is
constitutively activated and levels of phosphorylated ERK (p-
ERK) are raised in HCL [19,20]. As there is an essential
requirement for wild type BRAF in transducing BCR signals [5], it
remains to be established how mutant BRAF can affect BCR
function in HCL, given the requirements for dimerization of wild
type BRAF for ERK1/2 activation [4], and whether ERK1/2
activation can be enhanced by functional BCR signals for
downstream signals in HCL.
Here, we report on BCR function in mult-HCL, focusing on the
role of individual isotypes and their relevance to tumor persistence,
in cases uniformly displaying mutant BRAF V(600)E and mutated
IGHV genes. This study extends our preliminary observations on
BCR function in HCL [21].
Materials and Methods
Ethics
Ethical approval was obtained from institutional bodies. The
HCL samples were stored and provided by Professor H. Kluin-
Nelemans, and have been approved for use by Ethical Review by
the NHS Health Research Authority UK, NRES Committee
South Central under REC M228/02/t. The HCL samples
comprise an existing holding collected in 1980–1990 and for
which consent is waived by the Human Tissue Authority.
Patient Samples
Diagnosis of typical HCL disease was established by clinical
criteria, morphology of neoplastic cells in blood, histology of bone
marrow and spleen, cytochemical analysis, and immunophenotype
(CD11cHi/CD19+/CD22+/CD25+) [22]. Patients underwent sple-
nectomy, and disaggregated splenocytes were stored in liquid N2.
Unselected cases were analysed. Frozen splenocyte samples were
thawed, washed, resuspended and allowed to stabilise prior to use
(full details are given in Supporting Information; File S1).
Immunophenotyping
Multiparameter flow cytometry (FC) with fluorochrome conju-
gated F(ab’)2 antibodies was used to immunophenotype hairy cell
(HC) subpopulations in individual tumors [15,16] (detailed
protocol is described in File S1).
Analysis of IGHV Genes and BRAF V(600)E Mutation
Tumor-derived IGHV genes and the BRAF V(600)E mutation
were identified as reported [15,16,23]. DNA sequencing spectra
delineated between monoallelic and biallelic BRAF V(600)E
mutations [23].
BCR Induced Intracellular Calcium Flux
Washed cells were loaded with the free Ca2+ sensor dye Fluo-
3AM and labelled with anti-CD19/CD11c antibodies for FC, and
stimulated with isotype specific or sIgL antibodies for tracing Ca2+
flux (detailed protocol is described in File S1).
Phosflow Protocol for Measurement of BCR Induced ERK
Phosphorylation
This protocol utilized a mild alcohol permeabilization after
stimulating HCs with goat F(ab’)2 anti-human IgA, IgD, IgG, IgM,
kappa or lambda to assay ERK1/2 phosphorylation using a
specific a-phosphoERK1/2-alexafluor488 antibody. Data was
acquired on CD19+CD11cHi gated lymphocytes for analysis of
shifts in phosphoERK fluorescence by FC (detailed protocol is
described in File S1).
BCR Endocytosis
Two methods were employed: either cells were stained with a
FITC-labeled rabbit F(ab’)2 anti-goat F(ab’)2 and a secondary
antibody to detect remaining goat F(ab’)2 on the cell surface, or
stained with rabbit F(ab’)2 anti- human Ig antibodies, as for
immunophenotyping, to allow analysis of changes in paired IgH
and IgL chains (detailed protocol is described in File S1).
Induction of Intracellular Calcium Flux following BCR
Endocytosis
Endocytosis of sIg was induced as above, with pre-binding of
goat F(ab)2 anti-IgH or IgL, then incubated at 37uC, washed and
loaded with fluo3-AM, followed by staining with a-CD19-V450
and a-CD11c-APC (detailed protocol is described in File S1).
Induction of Apoptosis following BCR Stimulation
Splenocytes were stimulated with soluble goat F(ab)2 a-human
IgA, IgD, IgG, IgM, kappa or lambda antibody respectively or
with immunobead-conjugated anti-human IgA, IgG or IgM
coated immunobeads in medium for 2/3 hours at 37uC. Induction
of apoptosis was measured using Apostat or Apo2.7-PE as detailed
in File S1.
Analysis of Proliferation following BCR Stimulation
HCL cells were stimulated with F(ab)2 a-human IgA, IgD, IgG,
IgM, kappa or lambda at 37uC and proliferation assessed using a
metabolite capture Cell Proliferation Kit II (XTT) (detailed
protocol is described in File S1).
Hairy Cell Leukemia B Cell Receptor Isotype Roles
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Results
Phenotype, BRAF and IGHV Mutational Status
We utilized CD19+CD103+CD11cHi expression to gate specif-
ically on HCs, and F(ab’)2 antibodies to exclude non-specific FcR
binding. CD103 expression correlated tightly with CD11cHi
expression (Fig. S1), permitting use of CD19+CD11cHi FC gates
to delineate tumor cells and exclude non-tumor B-cells (n = 10
mult-HCL cases). To confirm this, tumor cells obtained in 2/2
cases by flow sorting using CD19+CD103+CD11cHIgates achieved
purities of 91.1–99.8%, and in these the tumor-derived IGHV
marker gene was found in .98% of all clones examined in each
case (data not shown). Splenic tumor burden ranged from 52–90%
using these markers (Table S1 in File S1).
The mult-HCL phenotype was confirmed by examining single
HCs by multiparameter FC (Fig. S1; Table S1 in File S1). These
data delineated 2 subsets by phenotype, differing by IgD co-
expression, with sIgk or sIgl or both light chains expressed.
In IgD+ve mult-HCL, with sIgD expressed in.90% tumor cells,
each case also displayed multiple isotypes, both pre-switched and
post-switched (n = 4 cases; Table S1 in File S1). Patterns of co-
expressed isotypes on individual HCs varied. In IgD+ve Cases 7
and 9, IgD/IgG/IgM/kappa were co-expressed on .90% of cells.
In IgD+ve Case 13, IgD/lambda were expressed on all cells with
subpopulations expressing IgA (26%), IgG (95%), IgM (89%) and
kappa (88%), and similarly, in IgD+ve Case 6 all cells expressed
IgD/lambda with subpopulations expressing IgA (34%), IgG
(62%), IgM (20%) and kappa (72%).
In IgD2ve mult-HCL, tumor cells displayed IgG/M or IgG/M/
A isotypes but clearly lacked surface IgD expression (n= 6 cases;
Table S1 in File S1). In IgD2ve Cases 2, 3 and 4, IgG/kappa was
expressed on 100% of cells, with a subpopulation of cells co-
expressing IgM (50–90%). In IgD2ve Case 5, 100% of cells
expressed IgA/IgG/lambda, with subpopulations of cells co-
expressing IgM (48%) or kappa (86%) respectively. IgD2ve Case
10 expressed IgG/lambda on 100% of cells, with subpopulations
of cells co-expressing IgA (72%) and IgM (18%), respectively
(Table S1 in File S1; Fig. S1). In IgD2ve Case 11 IgG/kappa was
expressed on all cells, with IgA and IgM co-expressed on 12% and
13% of cells, respectively.
Dual light chain expression was observed in 3 mult-HCL cases
(Cases 5,6,13; Table S1 in File S1), confirming our previous
observations [24]. In 8/8 cases examined, CD27 expression was
absent on gated tumor cells (Table S1 in File S1), as previously
reported [25].
The BRAF V(600)E mutation was verified in 10/10 cases (Table
S1 in File S1) by amplification and Sanger DNA sequencing [23];
in each case, the mutation was found to be monoallelic. IGHV
gene analysis delineated 10/10 cases as mutated (98.6–92.2%
homologous to germline), with clonally-derived multiple isotype
switched transcripts in the tumor population (Table S1 in File S1).
BCR Induced Ca2+ Flux
BCR stimulation triggers tyrosine kinase phosphorylation events
and activation of phospholipase C to release intracellular Ca2+
from the endoplasmic reticulum into the cytosol, and this can be
assayed using cytoplasmic dyes (fluo3-AM) that fluoresce in the
presence of free Ca2+. BCR mediated Ca2+ flux was examined in
HCs gated by CD19+CD11cHi (7/10) or CD19+CD103+CD11cHi
(3/10) expression. Initial studies indicated that anti-CD19/
CD103/CD11c antibodies respectively did not induce Ca2+ flux
(data not shown). All cases (10/10) revealed functional BCRs that
transduced Ca2+ flux (Fig. 1). However, striking differences
emerged between the IgD+ve and IgD2ve subsets. In IgD+ve cases
(6, 7, 9 and 13), invariably more than one sIgH isotype triggered
Ca2+ flux (Table 1). In these cases, IgD produced the predominant
response, while IgG and/or IgM were capable of stimulating lower
levels of flux. In contrast, in IgD2ve cases (2, 3, 4, 5, 10 and 11),
only signals via a single switched isotype (IgG/A) induced flux but
not the co-expressed IgM (cases 2, 3, 4, 5, 10 and 11) or IgG (case
5) or IgA (cases 10 and 11) (Table 1). While, in some IgD2ve cases
this lack of response may be linked to lower levels of surface
expression (IgA in case 11; IgM in cases 5, 10 and 11), this does
not account for lack of function in more highly co-expressed
isotypes (IgM in cases 2, 3 and 4; IgG in case 5; IgA in case 10).
These non-functional isotypes in IgD2ve cases are co-expressed at
comparable levels to functional isotypes in IgD+ve cases. It may
instead point to a selected feature that distinguishes the two mult-
HCL subsets.
This functional dichotomy was also accompanied by marked
differences in the patterns of Ca2+ flux observed. When IgD was
co-expressed, it tended to trigger persistent responses accompanied
by transient responses from the less prominent isotype(s) (Fig. 1),
whereas all flux responses in IgD2ve mult-HCL were of the fast
transient type (Table 1). In normal circulating B cells, IgD or IgM
stimuli induce persistent calcium flux (data not shown).
Overall, measurements of Ca2+ flux in mult-HCL were carried
out in 6/6 IgD2ve and 4/4 IgD+ve cases, confirming observations
in ‘biological’ replicates. Whether these patterns are consistently
observed in each IgD subset awaits further study when larger
cohorts are examined.
In relation to dual light chain expression, in the IgD+ve mult-
HCL Case 13 a low level of Ca2+ flux was observed via the second
light chain k in addition to the predominant l response; in Case 5
and 6, this cationic flux was only induced by the l chain (Table 1).
BCR Induced Downstream ERK Phosphorylation
Downstream BCR signals initiate ERK1/2 phosphorylation via
the MAPK pathway to mediate cellular responses. ERK1/2
phosphorylation was examined in mult-HCL able to induce Ca2+
flux by crosslinking BCR. In 7/7 cases examined from both
subsets, ERK1/2 phosphorylation was restricted to the IgH
isotype or single IgL that transduced Ca2+ flux via the BCR
(Table 1; Fig. 2). Negative control isotypes or IgL chosen as they
did not induce Ca2+ flux failed to phosphorylate ERK1/2,
demonstrating specific functional coupling (Table 1; Fig. 2). The
kinetics of ERK1/2 phosphorylation as compared to Ca2+ flux
varied. Although IgD-induced Ca2+ flux signals were generally
persistent (marked with ‘b’, Table 2), the corresponding ERK1/2
phosphorylation response tended to be transient (marked with ‘a’,
Table 2). In IgD2ve Cases 2, 3 and 5 where all calcium flux
responses had been fast transient (marked with ‘a’, Table 2), ERK
phosphorylation was predominantly fast transient (Table 2; Fig. 2,
upper panel).
BCR Endocytosis
Normal B cells endocytose the BCR following cognate
antigen recognition to mediate processing and presentation of
antigen [26]. In mult-HCL, BCR endocytosis following goat
F(ab’)2 anti-human IgH/IgL specific stimuli was evaluated by
two different methods. Firstly, by changes in levels of bound
stimulating antibody following endocytosis were measured by
staining with a FITC-labelled rabbit F(ab’)2 anti-goat F(ab’)2
secondary antibody (Fig. 3 A and Fig. S2 A, top panels).
Secondly, by changes in levels of expression of the stimulated
IgH isotype/IgL and of sIgH/IgL pairings by specific staining
with FITC- and PE-labeled rabbit F(ab’)2 anti-human Ig
antibodies (Fig. 3 A and S2 A, middle and lower panels).
Hairy Cell Leukemia B Cell Receptor Isotype Roles
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The latter method has the disadvantage that when staining for
the same IgH/IgL as stimulated, stearic hindrance may
exaggerate apparent loss of expression. This stearic hindrance
however is avoided with the anti-goat secondary antibody
method. Where feasible, Ca2+ flux was also evaluated following
endocytosis.
Two IgD+ve mult-HCL cases were examined. In Case 13 (sIgA+,
D+++, G+++, M++, k++, l+++; Table S1 in file S1), anti-IgD stimuli
reduced sIgD and sIgl expression via endocytosis, but had no
Figure 1. BCR induction of calcium flux is functionally intact in both IgD+ and IgD2ve mult-HCL. Ca2+ flux was measured in response to
goat F(ab’)2 anti-IgH or anti-IgL mediated BCR ligation using the cytoplasmic calcium-indicator dye Fluo3-AM. Unstimulated cells were recorded for
30 seconds prior to addition of goat F(ab’)2 polyclonal anti-Ig. Stimulated cells were then tracked for 5 minutes: cells were gated first on FSC/SSC,
then as CD19hiCD11chi for cases 1–9 or as CD19hiCD11chiCD103+ for cases 10–13 prior to analysis of Fluo3-AM fluorescence. The plots here show %
cells over threshold where the threshold is the 85th percentile of unstimulated cells. Ionomycin was used as control to achieve maximal Ca2+ flux.
doi:10.1371/journal.pone.0086556.g001
Table 1. Mult-HCL immunophenotype and isotype function in transducing Ca2+ flux to ERK 1/2 phosphorylation.
sIg status Case sIg Phenotype* Ca2+ flux
# ERK phosphorylation
$
A D G M K L A D G M K L A D G M K L
D-ve 2 – – +++ ++ +++ – – – +++a – ++a – ND ND ++a – +a ND
D-ve 3 – – +++ ++ +++ – – – +++a – ++a – ND ND ++a – +a ND
D-ve 4 – – +++ ++ +++ – – – +++a – ++a – ND ND ND ND ND ND
D-ve 5 +++ – +++ + ++ +++ ++a – – – – ++a ++d ND ND ND – ++d
D-ve 10 ++ – +++ + – +++ – – +++a – – +a ND ND ND ND ND ND
D-ve 11 + – +++ + +++ – – – +++a – +++a – ND ND ND ND ND ND
D+ve 6 + +++ ++ + ++ +++ +c +++b ++c – – +++b 2/+c +++a +/2c – – +a
D+ve 7 – +++ +++ +++ +++ – – +++b +c +/2c +++b – ND +++a +/2c – ++a ND
D+ve 9 – +++ +++ +++ +++ – – +++a ++c ++c +++a – ND +++a ++c +/2c +++a ND
D+ve 13 + +++ +++ ++ ++ +++ – +++b (+)c ++c (+)c ++b – ++b +c +a – ++a
*Surface immunoglobulin (sIg) phenotype data is reproduced from Table S1 to allow for ease of comparison when evaluating Ca2+ and ERK phosphorylation data.
#Intensity of Ca2+ flux responses is denoted by +/2; –,5% of cells responded, +10–35% of cells responded, ++35–70% of cells responded,+++.70% of cells responded.
Flux patterns are denoted by lower case letters; a-fast transient, b-fast persistent, c-slow biphasic/persistent, d-fast biphasic.
$
For ERK phosphorylation signal intensity is indicated by 2/+/++/+++ and type of signal by lower case letters as for Ca2+ flux: a- fast transient, b- fast persistent, c- slow
biphasic/persistent, d- fast biphasic.
doi:10.1371/journal.pone.0086556.t001
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effect on sIgk (Fig. S2 A, first column data). Anti-sIgl stimuli
triggered a reduction in sIgD, sIgM and sIgl levels (Fig. S2 A,
second column data), and a small reduction in sIgG expression but
no change in sIgA (data not shown). This effect on sIgG
endocytosis, in relation to high levels of expression and relatively
low levels of Ca2+ flux and ERK1/2 phosphorylation following
anti-sIgG perturbation (Table 1), suggests either a restricted
functional coupling or possibly a gradual loss of sIgG function. In
addition, anti-sIgM stimulation partly reduced sIgM expression
but had no measureable effect on slgl or sIgk (Fig. S2 A, third
column data) suggesting that in mult-HCL, pairings of sIgH
isotype occur with specific sIgL when dual light chains are
expressed on HCs and that only one sIgL chain retains
functionality. However, sIgA expression is relatively low on these
HCs and insufficient levels for effective cross-linking may explain
the lack of endocytosis and Ca2+ flux (Fig. S2 A; fourth column
data). Further analysis of Case 13 indicated that BCR endocytosis
using specific anti-sIg stimuli affected signal transduction to induce
Ca2+ flux, revealing fully functional internalisation events. Anti-
sIgD treatment completely ablated Igl induced Ca2+flux, while
endocytosis of sIgM greatly reduced it (Fig. S2 B, centre panel).
This confirms functional integrity of sIgM expression in IgD+ve
mult-HCL. Induction of endocytosis by anti-Igl stimuli reduced
measurable Ca2+ flux via sIgD (Fig. S2 B, left panel), but
Figure 2. BCR-induced signals trigger phosphorylation of ERK1/2 in mult-HCL. The BD phosflow assay system was used to measure
phosphorylation of ERK1/2 following BCR stimuli. Cells were stimulated using goat F(ab’)2 anti-Ig antibodies for indicated times, fixed, permeabilised
and CD19HICD11cHI lymphocytes examined for intensity of phosphorylated ERK1/2 staining. Patterns of ERK1/2 phosphorylation reflected induced
calcium flux. Two representative examples are shown. Upper Panel: In IgD2ve mult-HCL Case 3 anti-IgG or k stimuli induce Ca2+ flux and ERK1/2
phosphorylation. Notably, sIgM shown not to induce Ca2+ flux did not trigger ERK1/2 phosphorylation. Lower panel: In IgD+ mult-HCL Case 7, ERK1/2
phosphorylation patterns again reflected Ca2+ flux, both in intensity and type of signal. For example IgG-induced calcium flux was of low intensity
and slow (Table 1), which is mirrored by the ERK1/2 phosphorylation kinetics observed. Both panels: Note that at early time points (1–2 minutes) a
non-specific response is commonly observed in response to addition of antibody, as can be seen with anti-IgM and anti-l negative controls in Case 3.
doi:10.1371/journal.pone.0086556.g002
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completely ablated IgM-induced flux (Fig. S2 B, right panel). This
observation indicates kinetic differences in loss of functionality of
sIgH and sIgL, depending on specific endocytosis triggers.
Comparable patterns of BCR response were observed in IgD+ve
mult-HCL Case 6 (sIgD+++, G++, A+, M+, k++, l+++) where, due to
limited availability of material, a reduced analysis was performed.
Endocytosis by anti-IgD stimulation resulted in a reduction in
sIgD/sIgl, and a loss of l-induced Ca2+ flux, whereas the
corresponding anti-lmediated endocytosis resulted in reduction of
sIgl/sIgD expression and reduction in IgD induced Ca2+ flux
(data not shown).
In IgD2ve mult-HCL Cases 2, 3 and 4 (each with phenotype
sIgG+++, M++, k+++), endocytosis of sIgG and sIgk followed BCR
engagement with anti-sIgG, and endocytosis triggered via sIgk
reduced sIgG and sIgk expression, but had no effect on levels of
sIgM expression in 3/3 cases (Fig. 3 A and B; Table 1). This
confirmed a non-functional, immobilized state for sIgM in IgD2ve
mult-HCL, as Ca2+ flux was also absent via the sIgM isotype
(Table 1). The ability to induce Ca2+ flux through functionally
paired sIgGk was greatly reduced following endocytosis of sIgG or
sIgk (Fig. 3 C for Case 2).
BCR Mediated Selective Apoptosis
In each of 3 IgD2ve mult-HCL cases (5,10,11), stimulation via
functional sIgG or light chain with soluble goat F(ab’)2 anti-human
antibody induced significant levels of apoptosis as compared to
dysfunctional sIg isotype, which were used as controls (Fig. 4;
Table 2). In IgD2ve mult-HCL Case 10, where material was
available, we investigated the effect of immobilised antigen using
antibodies coupled to beads (Fig. 4 E). Surrogate antigen in this
format, which maximises cross-linking to limit endocytosis, also
triggered apoptosis but not above levels seen with soluble antibody
(Fig. 4 D; Table 2). In 2 IgD2ve mult-HCL cases (3,10), an
additional XTT based assay for proliferation showed no such
effects when stimulated with functional anti-sIg antibodies (Fig.
S3).
In IgD+ve mult-HCL analysis of apoptosis post-BCR stimuli was
restricted to a single case due to sample availability. For Case 13,
BCR retained functional sIgM/D/G but not IgA (Tables 1,2).
Using soluble anti-sIgM, small but significant apoptotic effects
were observed (Fig. 5), not recapitulated by dysfunctional sIgA. In
stark contrast, anti-sIgD signals did not trigger apoptosis and HCs
retained cellular integrity (Fig. 5 A). In the absence of additional
material from IgD+ve mult-HCL, we examined sIgD mediated
cellular responses in a separate IgD+ve single isotype (s)-HCL case.
Again, anti-sIgD stimuli did not trigger apoptosis (Fig. 5 B,C),
using soluble (Fig. 5 C) or immobilized anti-sIg stimuli (data not
shown), revealing isotype specific roles. Consequently, in 2/2
primary HCL samples signaling via sIgD appears to sustain tumor
cell integrity, to differ to effects of signal transduction via non-sIgD
isotypes in the BCR, and confirm observations in replicate cases. A
Table 2. Linking anti-sIg stimuli in HCL to downstream effects on tumor apoptosis.
% Cells apoptotic
sIg Assay 1 Assay 2
Case Status sIg Phenotype Functional BCR sIg
Stimulating
Antibody 2 hours 3 hours 2 hours 3 hours
3 D-ve IgG, IgM, kappa IgG, kappa CON (IgD) ND 5.65 ND 7.79
IgG ND 25.43*** ND 33.70****
kappa ND 23.40**** ND 23.63****
5 D-ve IgA, IgG, IgM, kappa, lambda IgA, lambda CON (IgD) 6.93 6.28 ND ND
IgA 19.45**** 12.80**** ND ND
lambda 14.70**** 16.83**** ND ND
10 D-ve IgA, IgG, IgM, lambda IgG, lambda CON (IgD) 9.13 9.50 12.60 9.50
IgG 21.48**** 29.20**** 29.23*** 32.10***
lambda 23.98**** 23.10*** 24.45*** 28.75****
CON#10 (IgA) ND 14.02 ND 10.40
IgG#10 ND 17.82* ND 16.52***
CON#20 (IgA) ND 14.04 ND 13.58
IgG#20 ND 23.68*** ND 18.68***
11 D-ve IgA, IgG, IgM, kappa IgG, kappa CON (IgD) 20.78 21.10 20.60 ND
IgG 35.53**** 34.08**** 32.83**** ND
kappa 39.65*** 41.53**** 38.55** ND
13 D+ve IgA, IgD, IgG, IgM,
kappa, lambda
IgD, IgM, IgG, lambda,
kappa
CON (IgA) ND 5.63 ND 4.58
IgD ND 5.93ns ND 4.33ns
IgM ND 8.95*** ND 5.50***
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Figure 3. Specific anti-sIg stimuli mediate endocytosis of functional BCR in IgD2ve mult-HCL. A representative example is shown. Cells
were stimulated with goat F(ab’)2 anti-Ig antibodies for 1 hour either at 37uC to allow apoptosis or at 4uC to prevent it. Changes in stimulated sIg
expression levels were then measured by secondary staining using mouse anti-goat F(ab)2 (A). Changes in expression of paired sIg were measured
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larger cohort study of IgD+ve mult-HCL cases will be required
nevertheless to examine how consistently IgD transduced signals
rescue HCs from apoptosis mediated by non-IgD isotypes but it is
clear from our data that this potential exists. Importantly, the lack
of any observed effects with anti-sIgD also validated assays with
other isotypes that did show significant apoptosis, under identical
conditions.
Discussion
This study addressed the intriguing question of a functional role
for individual variant sIg isotypes in mult-HCL, in a background
of mutant BRAF V(600)E, that constitutively activates a critical
component of the signaling cascade normally activated by a
functional BCR. Such a study is a pre-requisite to address whether
the BCR sustains tumor survival in-vivo in mult-HCL, and what
the nature of the antigen might be that triggers BCR signals.
Variant isotype function on HCs was analyzed by a rigorous
strategy that delineated CD19+ tumor cells by CD103 and/or
CD11cHi co-expression. Two functionally distinct mult-HCL sets
emerged by immunophenotype differing by IgD co-expression
(IgD+ve and IgD2ve), in which marked differences were apparent
in isotype function. In IgD+ve cases, more than one sIgH isotype
transduced Ca2+ flux with a persistent more robust pattern,
whereas in IgD2ve cases only a single switched isotype signaled
Ca2+ flux of a fast transient nature, despite the presence of other
sIgH isotypes. Functional Ca2+ flux via specific functional sIgH
isotype or sIgL associated tightly with the ability to endocytose
BCR, substantiating the linkage of endocytic internalization of the
BCR as dependent on functional signaling [3]. Endocytosis of
BCR allows B-cells to process and present cognate antigen, and
leads to degradation of internalized BCR [26]. Functional
observations were reproducibly observed in replicate cases, but
will require a wider dissection to establish definitive coherent
features with each subset. However, it needs to be recognized that
there are restrictions to the size of mult-HCL cohorts that can be
examined, given the rare nature of disease.
Functional sIg-mediated Ca2+ flux also associated closely with
amplification of ERK1/2 phosphorylation in mult-HCL. These
cases uniformly harbored a monoallelic BRAF V600E mutation,
which associates with constitutive activation of ERK1/2 reported
in HCL [19,20]. In normal B-cells, the wild type BRAF activation
loop (T599VKS602) induces kinase activity by conformational
changes [27], whereas the V600E mutation intrinsically achieves a
constitutively active conformation by mimicking the loop, leading
to chronic MEK/ERK signaling and transformation [28]. The
mutation bypasses several steps of BRAF activation and renders
the oncoprotein resistant to negative regulation [29]. It suggests
that in mult-HCL with monoallelic mutant BRAF V(600)E, that
either the wild type BRAF allele is being activated or that possibly
alternative pathways are being recruited by BCR transduced
signals to increase constitutive levels of ERK1/2 phosphorylation,
as observed in this study. HCL therefore presents a model disease
in which to dissect the molecular interplay between mutant B-RAF
and wild type A-RAF and C-RAF in transducing BCR-mediated
signals to the MAPK pathway. It also suggests that other receptor-
ligand interactions have potential to augment phospho-ERK levels
in HCs, as signalling conduits for specific tumor requirements.
IgD co-expression correlated with a functional assembly of each
variant isotype BCR on single HCs, suggesting that there are no
intrinsic steric constraints to multiple sIgH isotypes packaging in
the endoplasmic reticulum prior to surface expression. In contrast,
in IgD2ve mult-HCL dysfunctional sIgH isotypes were apparent,
notably with sIgM which failed to transduce measurable intracel-
lular signals and remained immobilized on the cell surface. It is
possible that sIgM or other isotypes in the IgD2ve subset may not
be expressed in a fully functional form. However, unless sIgM is
fully assembled, it fails to reach the cell surface [30]. The situation
with sIgG is less clear, and whether partially assembled and
dysfunctional sIgG molecules can be trafficked to the outer cell
membrane. Since sIgG is functional in some IgD2ve cases, it would
tend to argue that in the IgD2ve subset there appears to be a
successive loss of function of co-expressed isotype. Whether IgD2ve
cases result from loss of expression of IgD, with subsequent
successive loss of function of individual isotypes, remains to be
determined. We have previously suggested that individual variant
isotypes in mult-HCL arise by a mechanism of differential RNA
processing [15], and altered splicing events may underlie such IgD
loss. Two mult-HCL cases also displayed dual IgL expression, and
in these signals transduced by individual light chain to ERK1/2
phosphorylation were similarly restricted to a single sIgL type.
Notably, our data reveal that BCR mediated signals that lead to
apoptosis in HCs carrying mutant BRAF are isotype specific, using
both soluble and immobilised anti-sIgH stimuli, although due to
sample availability of this rare leukemia the latter observations
with immobilised ‘antigen’ were restricted, but nevertheless
experimentally replicated. These data suggest that in IgD2ve
mult-HCL, BCR transduced signals appear not to be relevant to
tumor survival. The data also suggest that signals downstream of
ERK1/2 phosphorylation bifurcate when initiated via the non-
IgD BCR complex (apoptosis) or via BRAF V(600)E (pro-survival).
They raise the intriguing possibility that acquisition of the BRAF
V(600)E mutation may be a mechanism to by-pass any BCR
signalling constraints in mult-HCL. Constitutively active BRAF
V(600)E in HCL would also abrogate a requirement for ligand
independent tonic signals via the BCR, as these signals are
transduced via ERK1/2 phosphorylation [31]. Tonic BCR signals
are a requirement in DLBCL [32], but not in FL [33]. BRAF
V(600)E in HCL clearly mediates pro-survival tumor signals, as
targeting the mutant protein with Vemurafenib (VEM) leads to
clinical resolution of disease [34–36].
BCR signaling in response to antigen in the absence of co-
stimuli (CD40:CD40L, TLR ligands, cytokines) is known to lead to
activation-induced cell death (AICD) [7–9]. This may involve
oligomeric assembly of higher-order BCR complex structure that
promotes activation but disrupt survival signals [37]. A key
using rabbit F(ab’)2 anti-Ig (B). Loss of functional sIg was further confirmed by measuring induction of Ca
2+ flux following endocytosis (C). Using the
anti-goat secondary antibody method stimulation of sIgG (A, left panel) and sIgk (A, middle panel) in Case 2 resulted in reduction of surface
expression of these two molecules. Stimulation of non-functional sIgM in this patient did not result in endocytosis (A, right panel). Using the rabbit
F(ab’)2 staining method stimulation of IgG (B, left panel) in Case 2 resulted in loss of sIgG (B, top left panel) and of sIgk (B, lower left panel). Stimulaton
of sIgk also triggered specific patterns of endocytosis, as shown by loss of sIgG and sIgk expression, but no change in sIgM expression (B, centre
panel). Stimulation of non-functional sIgM generated no changes in sIgM expression, or in sIgk expression (B, right panel). Inset shows a Table of the
sIg phenotype and functional isotypes in Case 2 included as a reference to correlate data (B, lower left). Following endocytosis of BCR by stimulation
with anti-Igk, the ability to induce Ca2+ flux via sIgG was completely ablated (C, left panel). Similarly following endocytosis of BCR with anti-sIgG, the
ability to induce Ca2+ flux via k was also negated (C, middle panel). No Ca2+ flux was induced through dysfunctional sIgM either before or after
endocytosis stimuli (C, right panel).
doi:10.1371/journal.pone.0086556.g003
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question that remains is to what extent B-cell tumors retain the
features of the cell of origin or normal B-cell counterpart that has
transformed. A role for T-cell dependent antigen activation in
origins of HCs in typical disease is as yet not defined. The absence
of T-cell derived co-stimuli via this route however is suggested in
HCL origins by lack of CD27 expression [1,25], implicating
origins from unusual memory B-cells [38]. SHM imprints are
evident in HCs, strongly suggesting a role for antigen in initiating
mutations with AID expressed, possibly at extra-follicular sites as
T-cell independent events [1,38]. BCR signals in IgD2ve mult-
HCL that lead to apoptosis may then be recapitulating AICD
observed in B-cells activated via the BCR in the absence of T-cell
help, and tend to support the contention that mult-HCL origins
implicate a T-cell independent pathway. Whether co-stimuli such
as TLR ligands can rescue the sIgM/G/A signalling cascade to
apoptosis in mult-HCL remains to be established.
In HCL, an opposing role of IgD as compared with other
isotypes is clearly apparent as sIgD transduced stimuli abrogate
pro-apoptotic signals from the BCR, revealing differences in
signals initiated by sIgD as compared to other isotypes. They
appear to parallel known divergence in IgD and IgM signals in
normal B-cells, with the same antigenic specificity. IgD elicits a
faster, stronger and more durable signal than IgM whereas only
the latter is under control of a negative feedback loop [39]. Despite
induction of active Ca2+ influx and activated tyrosine kinase
signals in both, only anti-IgM antibodies induce cell death,
indicative of differing downstream effector pathways [40]. In
malignant B-cells however, this difference in IgM and IgD roles is
not so readily apparent. In CLL, anti-IgD signals produce different
subset responses, in some cases preventing apoptosis above
spontaneous levels and in others accentuating them [41].
Apoptotic effects of soluble anti-sIgM in CLL can be abrogated
with immobilized anti-sIgM, suggesting that the level of cross-
linking impacts on downstream effects in these leukemic cells [42],
but not in HCs. In mult-HCL therefore, it is conceivable that sIgD
signals may rescue or over-ride pro-apoptotic stimuli by other
isotypes on the same HCs, leaving open a role for antigen in tumor
persistence in this subset of disease. However, the functional role of
sIgD in normal mature B-cells remains largely enigmatic [43],
creating some uncertainty whether sIgD signals in mult-HCL may
in fact be relevant in-vivo. Whether mult-HCL has entirely by-
passed any requirements for BCR, possibly due to mutant BRAF
constitutively activating the ERK1/2 pathway, remains at present
speculative.
Mult-HCL presents with unique features of multiple variant sIg
isotypes, and in this first study of the individual isotypes in the
BCR in this disease these isotypes emerge as differing functionally.
Of these, sIgD appears to have a potential role in tumor survival
and progression in-vivo, although as with normal B-cells, it is as yet
not clear whether specific sIgD signals are recruited for mult-HCL
survival. In non-IgD expressing mult-HCL, the possibility exists
that BCR signals that lead to apoptosis can be exploited to
synergise with VEM activity to maximize potency in refractory
disease. Targeting specific components of BCR signaling to ablate
tumors is already at the clinical application stage in several B-cell
malignancies [14], and understanding these pathways in mult-
Figure 4. Signalling via BCR using soluble or immobilised anti-
sIg antibodies induces apoptosis in IgD2ve mult-HCL. Tumor
cells were stimulated with goat F(ab’)2 anti-Ig antibodies at 20 mg/ml or
immobilised mouse anti-Ig using immunobeads at 10 or 20 mg/ml
(represented as IgG*, IgA*) for the indicated times at 37uC and early
onset apoptosis measured using the Apostat assay. Panels A–C show as
an example FC plots from Case 10 (sIgA++, IgG+++, IgM+, lambda+++, with
functional BCR isotypes IgG and l) revealing increased apoptosis (%
Apostat positive CD19HICD11cHICD103+ HCs) in response to soluble
(Panel B) and immobilised (Panel C) anti-IgG as compared to response
to non-functional isotype (anti-sIgA) as control (Panel A). Panel D shows
representative data from 1 of 2 replicate experiments using soluble
anti-sIg stimuli and increase in apoptosis in response to both functional
sIgG and l mediated signals as compared to a negative control isotype
that is not expressed (anti-sIgD). Staurosporin, included as a potential
agent for apoptosis, had no measurable apoptotic effect at time of
assay. Panel E shows data from 1 of 2 replicate experiments comparing
soluble –vs- immobilised anti-sIg stimuli for 3 h (data read-outs shown
in Table 2). The data shows that immobilised anti-sIg stimulation also
triggers apoptosis (at both 10 and 20 mg/ml) as compared to the
immobilised non-functional isotype control (anti-sIgA). Data were
analysed in PRISM using Student’s t-test with Welch’s correction. P-
values are denoted as: ns.0.05, *0.01–0.05, **0.01–0.001, ***0.001–
0.0001, ****,0.0001.
doi:10.1371/journal.pone.0086556.g004
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HCL informs both disease immunobiology and may have a
therapeutic relevance if VEM refractory disease appears.
Supporting Information
Figure S1 Multiparameter flow cytometry to define
immunophenotype of single tumor cells in mult-HCL.
Normal PBMNCs and isolated spleen cells from HCL cases were
immunophenotyped by gating on live cells and staining for CD19/
CD11c/CD103 and sIgH/L surface expression. (A) Following
FSC/SSC gating, CD19hiCD11chi cells (for 7/10 cases) or
CD19hiCD11chiCD103+ cells (for 3/10 cases) were examined for
sIg expression using rabbit F(ab’)2 anti-human Ig antibodies.
Normal PBMNC are virtually devoid of B-cells that are dual
CD11chiCD103+. (B) Representative example of immunopheno-
type of a mult-HCL tumor. IgD2ve mult-HCL Case 10
CD19hiCD11chiCD103+ cells display co-expression of sIgG and
l in 100% of HCL cells, with subsets of cells also sIgA (72%) and
sIgM (18%) positive.
(TIF)
Figure S2 Anti-sIg stimulation results in endocytosis of
functional BCR in IgD+ mult-HCL. Cells were stimulated
with goat F(ab’)2 anti-Ig antibodies for 1 hour either at 37uC to
allow endocytosis or at 4uC to prevent it. Changes in stimulated
sIg expression levels were then measured by secondary staining
using rabbit F(ab’)2 anti-goat F(ab)2 (A, top panels). Changes in
expression of paired sIg were measured using rabbit F(ab’)2 anti-Ig
(A, lower 2 rows). Loss of functional sIg was further confirmed by
measuring induction of calcium flux following endocytosis (B).
Using the anti-goat secondary antibody method (A, top panels)
stimulation via sIgD, l and sIgM in Case 13 as a representative
example resulted in reduction of surface expression of these
specific isotypes. Stimulation of non-functional sIgA in this tumor
did not result in endocytosis (A, top right panel). Using the rabbit
F(ab’)2 staining method (A, lower 2 rows) stimulation of sIgD (left
panels) in Case 13 resulted in loss of l, but not k light chain
expression. Lambda stimulation, second column, resulted in loss of
both surface IgD and IgM expression. IgM stimulation, third
column, resulted in marginal loss of l but not k surface expression.
Inset of a Table of the sIg phenotype and functional sIg isotypes is
included for reference purposes to evaluate data (A, lower right).
The ability to induce Ca2+ flux (B) via IgD was markedly reduced
following endocytosis by l stimulation (B, left panel). Ability to
induce Ca2+ flux via l was ablated by IgD endocytosis and also
greatly reduced by IgM endocytosis (B, centre panel). Similarly,
IgM induced flux was completely ablated following endocytosis
following anti-l stimulation (B, right panel).
(TIF)
Figure S3 Stimulation of BCR in mult-HCL triggers
apoptosis not proliferation. Cells were stimulated with goat
F(ab`)2 anti-Ig antibodies for 4 hours at 37uC and early apoptosis
was measured in CD19+CD11c+CD103+ HCL cells using
Apostat (left panels). Alternatively, XTT, a tetrazolium salt that
is cleaved to formazan in metabolically active cells only was used
to assess viability and proliferation following anti-BCR stimuli and
OD assayed at 490 nm (right panels). In 2/2 HCL cases (HCL
#3, top panels; HCL #10, lower panels) ApoStat assays revealed
significant increases in apoptosis in response to both functional
heavy (IgG) and light (k; HCL 3)/l;HCL 10) chain stimulation.
No apparent increase in numbers of metabolically active tumor
cells was observed in response to BCR stimulation in either HCL
case by XTT assay (right panels).
(TIF)
File S1 Contains supplementary materials and meth-
ods and Table S1.
(DOCX)
Figure 5. In IgD+ mult-HCL and IgD+ s-HCL anti-sIgD stimuli do
not trigger apoptosis. For IgD+ mult-HCL Case 13 (functional
isotypes for ERK1/2 phosphorylation: D++, G+, M+, l++) material was
available to evaluate stimulation with soluble goat F(ab’)2 anti-sIgD/l
antibodies or anti-sIgA as control (isotype not functional). Panel A
shows representative data from 1 of 2 replicate experiments assaying
apoptosis in CD19HICD11cHICD103+ tumor cells following stimulation.
Anti-sIgD stimulation did not induce apoptosis as compared to the non-
functional isotype control. Stimulation with soluble anti-sIgM did
induce a low but significant increase in apoptosis as this isotype is
functional. This lack of apoptotic effect in response to IgD stimulation
was further investigated in a single sIgD+ve s-HCL Case 15 (phenotype
summarised in Panel C). Stimulation via sIgD or slgl in this s-HCL case
did not induce apoptosis of CD19HICD11cHICD103+ tumor cells either in
response to soluble (Panel B) or immobilised anti-sIg (data not shown).
Data were analysed in PRISM using student’s t-test with Welch’s
correction. P-values are summarised as ns.0.05, *0.01–0.05, **0.01–
0.001, ***0.001–0.0001, ****,0.0001.
doi:10.1371/journal.pone.0086556.g005
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